TWI614244B - 吲哚啉-２-酮衍生物 - Google Patents

吲哚啉-２-酮衍生物 Download PDF

Info

Publication number
TWI614244B
TWI614244B TW105135829A TW105135829A TWI614244B TW I614244 B TWI614244 B TW I614244B TW 105135829 A TW105135829 A TW 105135829A TW 105135829 A TW105135829 A TW 105135829A TW I614244 B TWI614244 B TW I614244B
Authority
TW
Taiwan
Prior art keywords
dimethyl
methylpyrimidin
indololin
formula
compound
Prior art date
Application number
TW105135829A
Other languages
English (en)
Chinese (zh)
Other versions
TW201726653A (zh
Inventor
Delphine Gaufreteau
戴爾芬 勾佛雷提奧
Sabine Kolczewski
沙賓 考佐斯基
Jean-Marc Plancher
珍－馬可 帕蘭卻爾
Theodor Stoll
席爾朵 史鐸
Original Assignee
F. Hoffmann-La Roche Ag
赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag, 赫孚孟拉羅股份公司 filed Critical F. Hoffmann-La Roche Ag
Publication of TW201726653A publication Critical patent/TW201726653A/zh
Application granted granted Critical
Publication of TWI614244B publication Critical patent/TWI614244B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW105135829A 2015-11-06 2016-11-04 吲哚啉-２-酮衍生物 TWI614244B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15193355 2015-11-06
??15193355.3 2015-11-06

Publications (2)

Publication Number Publication Date
TW201726653A TW201726653A (zh) 2017-08-01
TWI614244B true TWI614244B (zh) 2018-02-11

Family

ID=54476823

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105135829A TWI614244B (zh) 2015-11-06 2016-11-04 吲哚啉-２-酮衍生物

Country Status (7)

Country Link
US (1) US10519140B2 (enExample)
EP (1) EP3371174B1 (enExample)
JP (1) JP6839184B2 (enExample)
CN (1) CN108137561B (enExample)
AR (1) AR106589A1 (enExample)
TW (1) TWI614244B (enExample)
WO (1) WO2017076842A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE050083T2 (hu) 2015-11-06 2020-11-30 Hoffmann La Roche Indolin-2-on származékok
JP6857653B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体
EP3371174B1 (en) 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives
JP6857651B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP2022550463A (ja) 2019-10-01 2022-12-01 エンピリアン ニューロサイエンス， インコーポレイテッド トリプタミン発現を調整する真菌の遺伝子操作
WO2021231933A1 (en) * 2020-05-15 2021-11-18 Neucyte Pharmaceuticals Anti-epileptic pharmaceutical compositions and use thereof
WO2023130075A2 (en) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Genetically modified organisms for producing psychotropic alkaloids
CN122122140A (zh) * 2024-09-27 2026-05-29 成都麻沸散医药科技有限公司 一种化合物及其制备方法和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201504223A (zh) * 2013-06-19 2015-02-01 Hoffmann La Roche 吲哚啉－２－酮或吡咯并－吡啶／嘧啶－２－酮衍生物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3935514A1 (de) 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW251284B (enExample) 1992-11-02 1995-07-11 Pfizer
DE4427648A1 (de) 1994-08-04 1996-02-08 Basf Ag N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
WO2000040581A1 (en) 1999-01-07 2000-07-13 American Home Products Corporation 3,4-dihydro-2h-benzo[1,4]oxazine derivatives
EP1303269B1 (en) 2000-06-29 2005-12-07 NeuroSearch A/S Use of 3-substituted oxindole derivatives as kcnq potassium channel modulators
WO2004060902A2 (en) 2002-12-31 2004-07-22 John K Buolamwini Novel nucleoside transport inhibitors
SK51052006A3 (sk) 2004-05-11 2007-05-03 Egis Gy�gyszergy�r Nyrt. Pyridínové deriváty alkyloxindolov ako aktívne látky voči 5-HT7 receptoru
US20060253263A1 (en) 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
MX2008016083A (es) 2006-06-26 2009-03-20 Helicon Therapeutics Inc Metodo para modular la excrecion de neuritas por el uso de un antagonista del receptor de galanina-3.
WO2008046083A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
EP2114921B1 (en) 2006-12-30 2012-12-26 Abbott GmbH & Co. KG Substituted oxindole derivative and its use as a vasopressin receptor ligand
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
JO3126B1 (ar) * 2007-11-14 2017-09-20 Janssen Pharmaceutica Nv مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
ES2590531T3 (es) 2012-09-13 2016-11-22 F. Hoffmann-La Roche Ag 2-oxo-2,3-dihidro-indoles para el tratamiento de trastornos del SNC
FR3017867A1 (fr) * 2014-02-21 2015-08-28 Inventiva Nouveaux composes de type phenylazetidine carboxylate ou carboxamide
PE20161476A1 (es) * 2014-06-26 2017-01-07 Hoffmann La Roche Derivados de indolin-2-ona o pirrolo-piridin-2-ona
EP3371174B1 (en) 2015-11-06 2021-03-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives
JP6857651B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体
JP6857653B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体
HUE050083T2 (hu) 2015-11-06 2020-11-30 Hoffmann La Roche Indolin-2-on származékok

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201504223A (zh) * 2013-06-19 2015-02-01 Hoffmann La Roche 吲哚啉－２－酮或吡咯并－吡啶／嘧啶－２－酮衍生物

Also Published As

Publication number Publication date
US10519140B2 (en) 2019-12-31
CN108137561A (zh) 2018-06-08
WO2017076842A1 (en) 2017-05-11
EP3371174B1 (en) 2021-03-17
JP2018538253A (ja) 2018-12-27
CN108137561B (zh) 2021-03-26
EP3371174A1 (en) 2018-09-12
AR106589A1 (es) 2018-01-31
US20180251450A1 (en) 2018-09-06
JP6839184B2 (ja) 2021-03-03
TW201726653A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
JP6839184B2 (ja) インドリン−２−オン誘導体
JP6857653B2 (ja) Ｃｎｓ及び関連障害の治療において使用するためのインドリン−２−オン誘導体
JP6130061B2 (ja) インドリン−２−オン又はピロロ−ピリジン／ピリミジン−２−オン誘導体
TWI631117B (zh) 吲哚啉－２－酮衍生物
TWI677495B (zh) 吲哚啉-2-酮衍生物
HK1254785B (en) Indolin-2-one derivatives
HK1254785A1 (en) Indolin-2-one derivatives
HK1257169B (en) Indolin-2-one derivatives for use in the treatment of cns and related disorders
BR112018008056B1 (pt) Derivados de indolin-2-ona, seu uso e composição farmacêutica que os compreende

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees